The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC); and (3) indinavir plus ZDV plus 3TC. This study also examines the resistance HIV may have to these drugs and if these drugs are effective over a long period of time.

Terfenadine, astemizole, cisapride, triazolam, or midazolam (competition for the enzyme cytochrome P-450 3A4 [CYP3A4] by indinavir could result in inhibition of metabolic breakdown of these drugs and create the potential for serious and/or life threatening events [i.e., cardiac arrhythmia, prolonged sedation]).

Rifampin or rifabutin (prohibited because of potential drug interaction with indinavir).

Prior treatment with efavirenz, 3TC, an NNRTI, or an HIV protease inhibitor.

Prior antiretroviral agent within 14 days of initiating study treatment.

Prior treatment (within 30 days of initiating study treatment) with any other experimental drug for any indication.

Patients must:

Have a diagnosis of HIV infection.

Have CD4 counts greater than or equal to 50 cell/mm3.

Have a life expectancy greater than or equal to 12 months.

Be post-pubescent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002410